Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Details Narrative)

v3.8.0.1
Stockholders' Equity (Details Narrative) - USD ($)
3 Months Ended
Mar. 19, 2018
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Number of shares acquired in exchange for common stock   2,090,301  
Common stock issued   35,272,626   35,272,626
Common stock shares outstanding   35,272,626   35,272,626
Recognization of license intangible asset   8,000,000    
Additional Paid-In Capital [Member]        
Recognization of license intangible asset   8,000,000    
CoNCERT Pharmaceuticals, Inc [Member]        
Option exercised in exchange for common stock $ 8,000,000      
Number of shares acquired in exchange for common stock 2,090,301      
Common stock, per share $ 3.83      
Percentage of common stock holdings 6.58%      
Precentage of issued and outstanding common stock diluted basis 5.93%      
Controlling interest, description Promet’s controlling interest was reduced from 90% to 84%.      
CoNCERT Pharmaceuticals, Inc [Member] | Additional Paid-In Capital [Member]        
Recognization of license intangible asset   8,000,000